PureTech’s Founded Entity Gallop Oncology Announces Positive …
BOSTON, December 05, 2025--PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data for LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia
PureTech’s Founded Entity Gallop Oncology to Present New Data …
LYT-200’s lead indication is acute myeloid leukemia (AML). Gallop Oncology was founded by and is currently a wholly-owned subsidiary of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), a …
PureTech’s Founded Entity Gallop Oncology Announces Positive …
Dec 5, 2025 · PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and …
PureTech's Gallop Oncology Reports 13.2-Month Survival with LYT-200 …
Dec 5, 2025 · Clinical Trial Results: Gallop Oncology's Phase 1b trial of LYT-200 in relapsed/refractory acute myeloid leukemia (AML) patients demonstrated a favorable …
Gallop Oncology
Gallop Oncology is a clinical-stage biopharma company leading development of drugs targeting galectin-9, a pivotal oncogenic and immunosuppressive regulator of cancer processes We are …
针对多种血液癌症，多款创新疗法展现积极临床试验 ...
1 day ago · [8] PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and …
PureTech’s Founded Entity Gallop Oncology to Present New Data …
Nov 3, 2025 · PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the …
PureTech’s Founded Entity Gallop Oncology to Present New Data …
Nov 3, 2025 · LYT-200’s lead indication is acute myeloid leukemia (AML). Gallop Oncology was founded by and is currently a wholly-owned subsidiary of PureTech Health plc (Nasdaq: …
LYT-200 - Puretech Health
Gallop Oncology™ is advancing a first-in-class, mechanistically differentiated approach to cancer treatment by targeting a novel, pro-tumor and immunosuppressive molecule. Gallop’s LYT-200 …
Gallop Oncology's LYT-200 Shows Strong Efficacy with 13.2 …
Dec 5, 2025 · Clinical Trial Progress: Gallop Oncology plans to release final survival data in the first half of 2026 and engage with regulatory authorities regarding the registration pathway for …